Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + bevacizumab ± chidamide ± capecitabine as first-line therapy for unresectable hepatocellular carcinoma
ChiCTR2500108129Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Group A: sintilimab + bevacizumab, Group B: chidamide + sintilimab + bevacizumab and Group C: chidamide + sintilimab + bevacizumab + capecitabine (3 arms). Primary endpoint: objective response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sintilimabbevacizumabtucidinostatcapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500108129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108129.